The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Sustained MRD negativity and long-term outcomes in DREAMM-8
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses long-term outcomes associated with sustained measurable residual disease (MRD) negativity in the Phase III DREAMM-8 study (NCT04484623). He highlights the low rate of progression and favourable long-term outcomes among patients achieving sustained MRD negativity with belantamab mafodotin, pomalidomide and dexamethasone. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Patients treated with belantamab mafodotin, pomalidomide and dexamethasone in the context of the DREAMM8 study had deep responses and about 60% of patients who achieved complete response, they also achieved minimal residual disease negativity. And among those patients who had sustained MRD negativity, meaning at least two MRD negative values, the rate of progression was very low. So these are the patients that appear to have an excellent outcome with long-term progression-free survival and overall survival...
Patients treated with belantamab mafodotin, pomalidomide and dexamethasone in the context of the DREAMM8 study had deep responses and about 60% of patients who achieved complete response, they also achieved minimal residual disease negativity. And among those patients who had sustained MRD negativity, meaning at least two MRD negative values, the rate of progression was very low. So these are the patients that appear to have an excellent outcome with long-term progression-free survival and overall survival. And patients who had low-risk myeloma were more likely to develop MRD negativity. So this is the main point from this particular analysis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
